Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Top Cited Papers
- 1 September 2012
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 17 (17-18), 988-997
- https://doi.org/10.1016/j.drudis.2012.05.012
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXRNature Reviews Molecular Cell Biology, 2012
- Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesityNature, 2012
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- Update on primary biliary cirrhosisDigestive and Liver Disease, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Primary biliary cirrhosisSeminars in Immunopathology, 2009
- Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat DietThe Journal of pharmacology and experimental therapeutics, 2008
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseHepatology, 2008
- Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markersHepatology, 2007
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006